Mycenax Biotech 

Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.